Santiago Thibaud
Overview
Explore the profile of Santiago Thibaud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bodnar S, Brander T, Gold J, Iverson A, Lagana A, Onel K, et al.
Semin Hematol
. 2024 Dec;
PMID: 39721861
Etiological links to multiple myeloma (MM) remain poorly understood, though emerging evidence suggests a significant hereditary component. This review integrates current literature on inherited factors contributing to MM risk, synthesizing...
2.
Chen L, Thibaud S, Bodnar S, Chari A, Richter J, Cho H, et al.
Blood Adv
. 2024 Nov;
9(1):176-179.
PMID: 39546749
No abstract available.
3.
Avigan Z, Bodnar S, Pan D, Catlett J, Richter J, Sanchez L, et al.
Blood Adv
. 2024 Oct;
9(1):202-206.
PMID: 39383457
No abstract available.
4.
Thibaud S, Subaran R, Newman S, Lagana A, Melnekoff D, Bodnar S, et al.
Blood Cancer Discov
. 2024 Sep;
5(6):428-441.
PMID: 39283238
First-degree relatives of patients with multiple myeloma are at increased risk for the disease, but the contribution of pathogenic germline variants (PGV) in hereditary cancer genes to multiple myeloma risk...
5.
Saldarriaga M, Pan D, Unkenholz C, Mouhieddine T, Velez-Hernandez J, Engles K, et al.
Blood Adv
. 2024 May;
8(15):3859-3869.
PMID: 38776397
B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T cells (CAR-Ts) used in multiple myeloma (MM) are rapidly becoming a mainstay in the treatment of relapsed/refractory (R/R) disease, and CAR-T expansion...
6.
Shah U, Moshier E, Derkach A, Huang Y, Mailankody S, Tan C, et al.
Blood Adv
. 2023 Sep;
8(1):236-247.
PMID: 37772981
Multiple myeloma (MM) is twice as common in Black individuals compared with in White individuals, and diabetes mellitus (DM) disproportionately affects Black patients. Although numerous studies have shown a correlation...
7.
Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al.
Blood Cancer Discov
. 2023 Sep;
4(6):440-451.
PMID: 37769148
Significance: To the best of our knowledge, this is the first study to comprehensively analyze risk factors and mitigation strategies to prevent infections in myeloma patients receiving anti-BCMA bispecific antibodies....
8.
Van Oekelen O, Nath K, Mouhieddine T, Farzana T, Aleman A, Melnekoff D, et al.
Blood
. 2022 Nov;
141(7):756-765.
PMID: 36327160
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR T) therapy has demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma, and now there are two US Food and Drug...
9.
Mouhieddine T, Moshier E, Thibaud S, Puliafito B, Rattu M, Jakubowski R, et al.
Bone Marrow Transplant
. 2022 Oct;
58(1):80-86.
PMID: 36261708
Rapidly progressing relapsed/refractory multiple myeloma (RRMM) patients with compromised marrow have limited treatment options. Thus, non-myeloablative chemotherapy with a stem cell boost (SCB) may provide disease control and hematopoietic improvement...
10.
Mouhieddine T, Van Oekelen O, Melnekoff D, Li J, Ghodke-Puranik Y, Lancman G, et al.
Blood Adv
. 2022 Aug;
7(6):1056-1064.
PMID: 36018226
T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and bispecific antibodies (BiAbs) has shown promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), leading to the...